MedTrace Logo

A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer

NCT06526832 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-07-30

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the BST02, a tumor infiltrating lymphocyte product, collected from the locally advanced liver cancer subjects

The main questions it aims to answer are:

1. Safety and tolerability of BST02.
2. Preliminary efficacy of BST02. Participants will receive a cytoreductive surgery to collect samples for the manufacture of BST02.

Participants will receive BST02 infusion followed by IL-2 infusion. Blood samples will be collected for the analysis of PK and safety.

Conditions

  • Locally Advanced Liver Carcinoma

Interventions

BIOLOGICAL

BST02

BST02 is a tumor infiltrating lymphocyte product manufactured from the sample collected in the patient's tumor lesion.

Sponsors & Collaborators

  • BioSyngen Pte Ltd

    lead INDUSTRY

Principal Investigators

  • Yaojun Zhang, Doctor · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-04
Primary Completion
2025-07-03
Completion
2025-12-03
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06526832 on ClinicalTrials.gov